论文部分内容阅读
目的观察肝复乐胶囊联合瘤内无水酒精注射术(PEIT)治疗原发性肝癌(PLC)的临床疗效。方法将74例原发性肝癌患者随机分为两组;对照组37例给予单纯PEIT术治疗,观察组37例给予PEIT术联合肝复乐胶囊口服治疗。结果观察组总有效率为89.19%,对照组为70.27%;两组临床疗效比较差异有统计学意义(P<0.05)。观察组1年生存率为83.87%,对照组为62.50%;两组生存率比较有显著性差异(P<0.05)。两组2年生存率比较无显著性差异(P>0.05)。结论肝复乐胶囊联合PEIT能提高PLC的临床疗效和延长生存期。
Objective To observe the clinical efficacy of Ganfural capsule combined with intratumoral alcohol injection (PEIT) in the treatment of primary hepatocellular carcinoma (PLC). Methods 74 patients with primary liver cancer were randomly divided into two groups; 37 patients in the control group were treated with PEIT alone and 37 patients in the observation group were treated with PEIT combined with Ganfule capsule. Results The total effective rate was 89.19% in the observation group and 70.27% in the control group. There was significant difference in clinical curative effect between the two groups (P <0.05). The 1-year survival rate was 83.87% in the observation group and 62.50% in the control group. There was significant difference between the two groups (P <0.05). There was no significant difference in 2-year survival rate between the two groups (P> 0.05). Conclusion Ganfural capsule combined with PEIT can improve the clinical efficacy of PLC and prolong survival.